Sun Pharmaceutical Industries Ltd

Sun Pharma.Inds. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Sun Pharmaceutical Industries Ltd

₹ 1,782 0.12%
05 Jun - close price
sunpharma.com BSE: 524715 NSE: SUNPHARMA
About

Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market.[1] It is the largest pharmaceutical company in India.[2]

Key Points

Product Offerings
The company produces a range of generic and specialty medications for chronic and acute conditions. Its product portfolio includes generics, branded generics, specialty pharmaceuticals, advanced technology-based products, antiretrovirals, active pharmaceutical ingredients (APIs), and intermediates. It offers medications in multiple dosage forms, such as injectables, sprays, ointments, creams, liquids, tablets, and capsules. [1] [2]The company offers 26+ products in the global specialty market, with a strategic focus on dermatology, ophthalmology, and onco-dermatology segments. [3]

Website BSE NSE
  • Market Cap ₹ 4,27,609 Cr.
  • Current Price ₹ 1,782
  • High / Low ₹ 1,917 / 1,547
  • Stock P/E 34.3
  • Book Value ₹ 348
  • Dividend Yield 0.90 %
  • ROCE 20.5 %
  • ROE 16.0 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 34.1%

Cons

  • The company has delivered a poor sales growth of 11.8% over past five years.
  • Working capital days have increased from 102 days to 185 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Sensex Nifty 50 BSE 500 BSE Healthcare BSE 100

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
10,931 11,941 12,192 12,381 11,983 12,653 13,291 13,675 12,959 13,851 14,478 15,521 14,612
8,129 8,609 9,013 8,904 8,948 9,045 9,352 9,666 9,243 9,550 9,951 10,572 10,658
Operating Profit 2,802 3,332 3,179 3,477 3,035 3,608 3,939 4,009 3,716 4,302 4,527 4,948 3,954
OPM % 26% 28% 26% 28% 25% 29% 30% 29% 29% 31% 31% 32% 27%
202 -118 294 180 504 533 354 149 251 -354 470 89 458
Interest 93 81 49 35 74 62 69 52 49 75 100 78 86
Depreciation 672 651 633 622 650 655 626 631 664 701 730 732 775
Profit before tax 2,240 2,481 2,791 3,000 2,816 3,424 3,598 3,476 3,254 3,173 4,168 4,227 3,551
Tax % 10% 19% 14% 14% 5% 16% 16% 16% 34% 27% 25% 20% 23%
1,983 2,006 2,385 2,561 2,659 2,861 3,037 2,913 2,154 2,293 3,125 3,381 2,710
EPS in Rs 8.27 8.43 9.90 10.52 11.06 11.82 12.67 12.10 8.96 9.50 13.00 14.04 11.31
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
27,392 28,487 31,578 26,489 29,066 32,838 33,498 38,654 43,886 48,497 52,578 58,462
19,498 20,313 21,476 20,858 22,689 25,855 25,028 28,397 32,235 35,479 37,464 40,731
Operating Profit 7,894 8,174 10,102 5,631 6,377 6,983 8,470 10,258 11,650 13,018 15,114 17,731
OPM % 29% 29% 32% 21% 22% 21% 25% 27% 27% 27% 29% 30%
283 -42 610 -135 -258 382 -3,449 -3,505 459 865 1,444 664
Interest 579 523 400 518 555 303 141 127 172 238 231 339
Depreciation 1,195 1,038 1,265 1,500 1,753 2,053 2,080 2,144 2,529 2,557 2,575 2,938
Profit before tax 6,403 6,571 9,048 3,479 3,810 5,010 2,799 4,481 9,408 11,088 13,752 15,119
Tax % 14% 14% 13% 26% 16% 16% 18% 24% 9% 13% 20% 24%
5,476 5,658 7,846 2,542 3,208 4,172 2,272 3,389 8,513 9,610 10,965 11,509
EPS in Rs 21.92 18.89 29.03 8.73 11.11 15.69 12.10 13.64 35.32 39.91 45.55 47.84
Dividend Payout % 14% 5% 12% 23% 25% 25% 62% 73% 33% 34% 35% 33%
Compounded Sales Growth
10 Years: 7%
5 Years: 12%
3 Years: 10%
TTM: 11%
Compounded Profit Growth
10 Years: 10%
5 Years: 17%
3 Years: 13%
TTM: 9%
Stock Price CAGR
10 Years: 9%
5 Years: 21%
3 Years: 22%
1 Year: 6%
Return on Equity
10 Years: 14%
5 Years: 16%
3 Years: 16%
Last Year: 16%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 207 241 240 240 240 240 240 240 240 240 240 240
Reserves 25,431 32,742 36,400 38,074 41,169 45,025 46,223 47,771 55,755 63,427 71,978 83,330
8,996 8,497 9,832 10,385 10,514 8,315 3,869 1,290 6,886 3,274 2,362 4,627
14,089 13,948 14,624 15,598 12,666 14,615 17,291 20,474 17,831 18,387 17,328 20,588
Total Liabilities 48,723 55,428 61,095 64,297 64,590 68,194 67,622 69,776 80,712 85,328 91,908 108,785
12,682 15,872 17,675 18,853 21,837 22,847 21,553 22,665 24,065 23,248 22,586 34,493
CWIP 2,039 2,175 2,801 2,465 1,411 1,220 1,567 1,287 4,973 5,354 6,644 1,381
Investments 2,716 1,830 1,192 7,143 7,903 10,143 9,612 12,849 14,824 15,026 18,354 24,723
31,286 35,550 39,427 35,837 33,439 33,984 34,890 32,975 36,849 41,700 44,324 48,189
Total Assets 48,723 55,428 61,095 64,297 64,590 68,194 67,622 69,776 80,712 85,328 91,908 108,785

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
5,616 6,686 7,082 3,907 2,196 6,555 6,170 8,985 4,959 12,135 14,072 12,419
-1,502 -3,949 -4,186 -3,104 -310 -2,225 407 -5,556 -7,220 -763 -5,183 -11,344
-1,187 -1,889 -2,285 -1,539 -2,731 -5,715 -5,980 -5,193 2,376 -6,710 -7,906 -2,513
Net Cash Flow 2,927 848 611 -736 -844 -1,386 596 -1,765 115 4,662 983 -1,437
Free Cash Flow 3,316 3,353 3,492 2,013 -966 5,105 5,097 7,550 2,895 9,964 12,005 8,906
CFO/OP 93% 106% 90% 83% 48% 113% 85% 78% 56% 105% 96% 83%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 68 87 83 108 112 105 99 99 95 85 91 97
Inventory Days 307 370 307 338 366 311 378 315 360 338 348 363
Days Payable 178 207 197 234 192 142 167 158 194 194 210 232
Cash Conversion Cycle 197 251 193 212 285 274 310 255 261 229 228 228
Working Capital Days -7 37 -4 -31 31 51 51 47 40 55 65 185
ROCE % 23% 18% 20% 10% 10% 10% 13% 17% 16% 17% 20% 21%

Insights

In beta
Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Formulation Sales by Geography - India
Rs Million

Log in to view insights

Please log in to see hidden values.

Login
Cumulative ANDAs Approved (US)
Number
India Pharmaceutical Market Share
%
Number of Global Manufacturing Facilities
Sites
R&D Spend as % of Sales
%
India Field Force Size
Personnel
Sales per Medical Representative (India)
Rs Million
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48%
16.48% 16.78% 17.08% 17.72% 17.23% 18.01% 18.04% 17.96% 17.26% 16.55% 16.12% 15.94%
19.65% 19.56% 19.42% 18.71% 19.17% 18.48% 18.43% 18.58% 19.38% 20.12% 20.72% 21.00%
0.09% 0.10% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11%
9.28% 9.05% 8.92% 8.97% 9.00% 8.89% 8.92% 8.86% 8.76% 8.72% 8.57% 8.48%
No. of Shareholders 6,24,5616,16,5886,12,6266,31,3926,73,2176,57,3176,89,6237,04,9837,23,7707,43,8777,10,9006,90,957

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls